Rein Therapeutics develops inhaled drug candidates for rare lung diseases, led by a treatment for idiopathic pulmonary fibrosis. RNTX reports earnings on Fri, Nov 13, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Aug 18 | HC Wainwright & Co. | Reiterated | Buy | |
| Jul 20 | Maxim Group | Initiated | Buy | |
| Jun 1 | HC Wainwright & Co. | Maintained | Buy |
Whale Options Flow
90DNo whale options trades in RNTX in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether RNTX is in one of them and how their past RNTX trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered RNTX in an article yet. Here's the latest on the wider market.
About Rein Therapeutics
Rein Therapeutics is a biopharmaceutical company based in Austin, Texas, that develops treatments for rare lung diseases with few effective options. Its lead candidate, LTI-03, is an inhaled peptide being studied for idiopathic pulmonary fibrosis, a progressive lung disease. The company has paused work on its other candidates while it focuses on LTI-03. Its target patients are people living with lung fibrosis and related conditions.
- Headquarters
- Austin, TX